First New Essential Tremor Therapy in 50+ Years: Goldman Bullish on Praxis Precision
Strong outlook for ulixacaltamide and relutrigine approvals by early 2027.
NOTRELOAD AI
Analyst Upgrade Boosts BeOne Medicines as Brukinsa Outlook Strengthens
Jefferies upgraded BeOne Medicines, citing strong Brukinsa growth, promising cancer drugs, and potential 27% stock upside.
Goldman Sachs Sees 46% Upside in NIO as It Upgrades Rating to Buy
Strong deliveries, premium margins, and expected 2026 profitability drive the bullish call.
TSMC Q2 Results Signal Continued AI Strength as Revenue Jumps 36%
June sales set a new monthly record. Full earnings expected July 16.
CONMED Weighs Strategic Sale as Takeover Interest Emerges
The Florida-based surgical device maker faces margin pressures but sees strong interest from acquirers.
Letterboxd in Talks for $250 Million Sale as Netflix, Sony, and Paramount Circle the Film Platform
Concerns grow over the platform’s independence as it hits 30 million users.